keyword
MENU ▼
Read by QxMD icon Read
search

Dolutegravir

keyword
https://www.readbyqxmd.com/read/28079545/efficacy-and-tolerability-of-dolutegravir-and-two-nucleos-t-ide-reverse-transcriptase-inhibitors-in-hiv-1-positive-virologically-suppressed-patients
#1
Alberto Borghetti, Gianmaria Baldin, Amedeo Capetti, Gaetana Sterrantino, Stefano Rusconi, Alessandra Latini, Andrea Giacometti, Giordano Madeddu, Chiara Picarelli, Ramona De Marco, Maria V Cossu, Filippo Lagi, Roberto Cauda, Andrea De Luca, Simona Di Giambenedetto
No abstract text is available yet for this article.
January 28, 2017: AIDS
https://www.readbyqxmd.com/read/28079544/discontinuation-of-treatment-and-adverse-events-in-an-italian-cohort-of-patients-on-dolutegravir
#2
Paolo Bonfanti, Giordano Madeddu, Roberto Gulminetti, Nicola Squillace, Giancarlo Orofino, Paola Vitiello, Stefano Rusconi, Benedetto M Celesia, Paolo Maggi, Elena Ricci
No abstract text is available yet for this article.
January 28, 2017: AIDS
https://www.readbyqxmd.com/read/28051809/pregnancy-related-changes-of-antiretroviral-pharmacokinetics-an-argument-for-tdm
#3
Francesco R Simonetti, Dario Cattaneo, Nadia Zanchetta, Vania Giacomet, Valeria Micheli, Nadia Ciminera, Cristina Gervasoni
Here we describe a case of an HIV-infected young woman with extensive drug-resistant virus, who was successfully switched from a raltegravir-based regimen to a dolutegravir-based intensified antiretroviral regimen a few days before scheduled caesarean section because of the still detectable viral load. The trough concentrations of all antiretroviral drugs before and after delivery are also described.Our case underlines both the difficult management of young women, HIV-infected at young age with very limited treatment options and the great variability in the pregnancy-related physiologic changes affecting the pharmacokinetics of antiretrovirals...
January 4, 2017: Antiviral Therapy
https://www.readbyqxmd.com/read/28008867/dolutegravir-plasma-concentrations-according-to-companion-antiretroviral-drug-unwanted-drug-interaction-or-desirable-boosting-effect
#4
Dario Cattaneo, Davide Minisci, Valeria Cozzi, Agostino Riva, Paola Meraviglia, Emilio Clementi, Massimo Galli, Cristina Gervasoni
BACKGROUND: Studies in healthy volunteers have shown that the recently approved HIV integrase inhibitor dolutegravir has limited drug-to-drug interaction profile. Here we carried out a pharmacokinetic survey in HIV-infected patients given dolutegravir as part of their antiretroviral therapy. METHODS: Dolutegravir plasma trough concentrations were measured in 78 HIV infected patients given the drug in combination with a protease inhibitor, a non nucleoside reverse transcriptase inhibitor or abacavir/lamivudine...
December 23, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27999056/switching-from-a-ritonavir-boosted-pi-to-dolutegravir-as-an-alternative-strategy-in-virologically-suppressed-hiv-infected-individuals
#5
Eugènia Negredo, Vicente Estrada, Pere Domingo, Maria Del Mar Gutiérrez, Gracia M Mateo, Jordi Puig, Anna Bonjoch, Arelly Ornelas, Patricia Echeverría, Carla Estany, Jessica Toro, Bonaventura Clotet
BACKGROUND: Switching from PIs to dolutegravir in virologically suppressed HIV-infected individuals has not been assessed. OBJECTIVES: The principal aim was to assess the evolution of bone mineral density (BMD) when switching from a ritonavir-boosted PI to dolutegravir in HIV-infected patients with osteopenia or osteoporosis. The secondary objective was to assess the antiviral efficacy and safety of the switch therapy. METHODS: This randomized, multicentre study assessed changes in BMD, bone turnover markers, and antiviral efficacy and safety in 73 virologically suppressed patients with osteopenia/osteoporosis taking a ritonavir-boosted PI plus abacavir/lamivudine who were randomized to switch from PI to dolutegravir (DOLU group, n = 37) or continue with a PI (PI group, n = 36)...
December 20, 2016: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/27999055/unravelling-the-dynamics-of-selection-of-multiresistant-variants-to-integrase-inhibitors-in-an-hiv-1-infected-child-using-ultra-deep-sequencing
#6
Karl Stefic, Maud Salmona, Marisa Capitao, Marion Splittgerber, Zoha Maakaroun-Vermesse, Marie-Laure Néré, Louis Bernard, Marie-Laure Chaix, Francis Barin, Constance Delaugerre
BACKGROUND: Ultra-deep sequencing (UDS) allows detection of minority resistant variants (MRVs) with a threshold of 1% and could be useful to identify variants harbouring single or multiple drug-resistance mutations (DRMs). OBJECTIVES: We analysed the integrase gene region longitudinally using UDS in an HIV-1-infected child rapidly failing a raltegravir-based regimen. METHODS: Longitudinal plasma samples at baseline and weeks 4, 8, 13, 17 and 39 were obtained, as well as the mother's baseline plasma sample...
December 20, 2016: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/27999017/efficacy-and-tolerance-of-dolutegravir-based-combined-art-in-perinatally-hiv-1-infected-adolescents-a-french-multicentre-retrospective-study
#7
Coralie Briand, Catherine Dollfus, Albert Faye, Elie Kantor, Véronique Avettand-Fenoel, Marion Caseris, Diane Descamps, Véronique Schneider, Marie-Dominique Tabone, Geneviève Vaudre, Florence Veber, Stéphane Blanche, Pierre Frange
OBJECTIVES: To assess the safety and efficacy of a dolutegravir-based regimen in perinatally HIV-1-infected adolescents. PATIENTS AND METHODS: We conducted a retrospective multicentre study of 50 adolescents beginning dolutegravir-based treatment regimens between January 2014 and December 2015. Clinical and biological data collected before and after dolutegravir initiation were analysed. The primary endpoint was the proportion of patients achieving a plasma viral load (PVL) <50 copies/mL within 3 months of dolutegravir initiation (for patients with detectable viraemia at baseline) and maintaining virological suppression (PVL <50 copies/mL) until the last follow-up visit (for all patients)...
December 20, 2016: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/27999010/pharmacokinetics-of-dolutegravir-and-rilpivirine-in-combination-with-simeprevir-and-sofosbuvir-in-hiv-hepatitis-c-virus-coinfected-patients-with-liver-cirrhosis
#8
Marco Merli, Laura Galli, Letizia Marinaro, Alessandra Ariaudo, Emanuela Messina, Caterina Uberti-Foppa, Antonella Castagna, Antonio D'Avolio, Adriano Lazzarin, Stefano Bonora, Hamid Hasson
OBJECTIVES: To evaluate the plasma trough concentrations (Ctrough) of dolutegravir and rilpivirine used in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus (HCV)-coinfected patients with liver cirrhosis. Virological efficacy and safety of both ART and anti-HCV therapy were assessed. PATIENTS AND METHODS: A prospective observational study in HIV/HCV-coinfected patients with liver cirrhosis on ART with dolutegravir plus rilpivirine and treated with simeprevir plus sofosbuvir (±ribavirin) was conducted...
December 20, 2016: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/27984559/psychiatric-symptoms-in-patients-receiving-dolutegravir
#9
Anna Fettiplace, Chris Stainsby, Alan Winston, Naomi Givens, Sarah Puccini, Vani Vannappagari, Ricky Hsu, Jennifer Fusco, Romina Quercia, Michael Aboud, Lloyd Curtis
INTRODUCTION: Psychiatric symptoms are reported to occur frequently in people living with HIV and may be associated with specific antiretrovirals. We analysed psychiatric symptoms observed with dolutegravir and other frequently prescribed anchor drugs. METHODS: Selected psychiatric symptoms (insomnia, anxiety, depression, and suicidality) occurring in HIV-positive patients during dolutegravir treatment across 5 randomized clinical trials (3 double-blind), in the Observational Pharmaco-Epidemiology Research & Analysis (OPERA®) cohort, and among cases spontaneously reported to ViiV Healthcare were analysed...
December 7, 2016: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/27977411/dolutegravir-monotherapy-when-should-clinical-practice-be-clinical-research
#10
Joel Gallant, Jeremy Sugarman
No abstract text is available yet for this article.
December 15, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27912079/a-humanized-mouse-model-for-hiv-2-infection-and-efficacy-testing-of-a-single-pill-triple-drug-combination-anti-retroviral-therapy
#11
Shuang Hu, Charles Preston Neff, Dipu Mohan Kumar, Yuichiro Habu, Sarah R Akkina, Takahiro Seki, Ramesh Akkina
While HIV-2 is a causative agent for AIDS in addition to the better studied HIV-1, there is currently no suitable animal model for experimental studies for HIV-2 infection and evaluating promising drugs in vivo. Here we evaluated humanized mice for their susceptibility to HIV-2 infection and tested a single-pill three drug formulation of anti-retrovirals (NRTIs abacavir and lamivudine, integrase inhibitor dolutegravir) (trade name, Triumeq(R)). Our results showed that hu-mice are susceptible to HIV-2 infection showing persistent viremia and CD4 T cell loss, key hallmarks of AIDS pathogenesis...
January 15, 2017: Virology
https://www.readbyqxmd.com/read/27893693/two-case-reports-of-severe-myocarditis-associated-with-the-initiation-of-dolutegravir-treatment-in-hiv-patients
#12
Keren Mahlab-Guri, Ilan Asher, Shira Rosenberg-Bezalel, Daniel Elbirt, Michael Burke, Zev M Sthoeger
RATIONALE: The integrase inhibitor dolutegravir is now recommended as first-line treatment for HIV. A single case of myocarditis after treatment with dolutegravir was reported in the FLAMINGO trial. We present here 2 cases of severe myocarditis that occurred shortly after the initiation of dolutegravir treatment. PATIENTS CONCERNS: The first case is a 45-year-old female who developed severe congestive heart failure and died, weeks after the initiation of dolutegravir treatment (for simplification of her antiretroviral regimen)...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27882352/quantitative-evaluation-of-the-antiretroviral-efficacy-of-dolutegravir
#13
Sarah B Laskey, Robert F Siliciano
The second-generation HIV-1 integrase strand transfer inhibitor (InSTI) dolutegravir (DTG) has had a major impact on the treatment of HIV-1 infection. Here we describe important but previously undetermined pharmacodynamic parameters for DTG. We show that the dose-response curve slope, which indicates cooperativity and is a major determinant of antiviral activity, is higher for DTG than for first-generation InSTIs. This steepness does not reflect inhibition of multiple steps in the HIV-1 life cycle, as is the case for allosteric integrase inhibitors and HIV-1 protease inhibitors...
November 17, 2016: JCI Insight
https://www.readbyqxmd.com/read/27860104/higher-rates-of-neuropsychiatric-adverse-events-leading-to-dolutegravir-discontinuation-in-women-and-older-patients
#14
C Hoffmann, T Welz, M Sabranski, M Kolb, E Wolf, H-J Stellbrink, C Wyen
OBJECTIVES: Dolutegravir (DTG), a second-generation integrase strand transfer inhibitor (INSTI), is now among the most frequently used antiretroviral agents. However, recent reports have raised concerns about potential neurotoxicity. METHODS: We performed a retrospective analysis of a cohort of HIV-infected patients who had initiated an INSTI in two large German out-patient clinics between 2007 and 2016. We compared discontinuation rates because of adverse events (AEs) within 2 years of starting treatment with dolutegravir, raltegravir or elvitegravir/cobicistat...
January 2017: HIV Medicine
https://www.readbyqxmd.com/read/27846791/clinical-experience-with-dolutegravir-abacavir-lamivudine-in-hiv-hcv-co-infected-patients-treated-with-a-sofosbuvir-based-regimen-safety-and-efficacy
#15
Tamara M Johnson, Raymund Sison, James P Fallon, Prerak P Shukla, Sristi Bhattarai, Herbert Galang, Richard Habeeb, Jihad Slim
BACKGROUND: There is no known reason to suspect an adverse drug interaction between dolutegravir-based antiretroviral therapy and sofosbuvir, simeprevir, or ledipasvir. There is a paucity of clinical data for this combination. METHODS: Prospective, open-label study of patients with HIV well controlled on dolutegravir, abacavir, and lamivudine, who were co-infected with HCV genotype 1, and required therapy with simeprevir plus sofosbuvir or sofosbuvir/ledipasvir single-tablet regimen (STR) for 12 weeks...
November 2016: HIV Clinical Trials
https://www.readbyqxmd.com/read/27834772/early-neuropsychological-adverse-events-after-switching-from-pi-r-to-dolutegravir-could-be-related-to-hyperthyroidism-in-patients-under-levothyroxine
#16
Jean-Luc Berger, Yohan Nguyen, Delphine Lebrun, Caroline Migault, Maxime Hentzien, Hélène Marty, Firouzé Bani-Sadr
No abstract text is available yet for this article.
December 11, 2016: Antiviral Therapy
https://www.readbyqxmd.com/read/27826447/experience-of-dolutegravir-in-hiv-infected-treatment-naive-patients-from-a-tertiary-care-university-hospital-in-ireland
#17
Sarmad Waqas, Mairead O'Connor, Ciara Levey, Paddy Mallon, Gerard Sheehan, Anjali Patel, Gordana Avramovic, John S Lambert
OBJECTIVE: Dolutegravir, an HIV integrase inhibitor, is a relatively new treatment option. To assess the tolerability, side effects, and time to viral decline to non-detectable in patients newly started on dolutegravir. METHODS: Retrospective health care record of 61 consecutive HIV treatment-naive patients started on dolutegravir was reviewed and analysed on SPSS. RESULTS: The mean initial viral load was 160826.05 copies/mL (range, 79-1,126,617 copies/mL)...
2016: SAGE Open Medicine
https://www.readbyqxmd.com/read/27824625/intolerance-of-dolutegravir-containing-combination-antiretroviral-therapy-regimens-in-real-life-clinical-practice
#18
Mark G J de Boer, Guido E L van den Berk, Natasja van Holten, Josephine E Oryszcyn, Willemien Dorama, Daoud Ait Moha, Kees Brinkman
OBJECTIVE: Dolutegravir (DGV) is one of the preferred antiretroviral agents in first-line combination antiretroviral therapy (cART). Though considered to be a well tolerated drug, we aimed to determine the actual rate, timing and detailed motivation of stopping DGV in a real-life clinical setting. DESIGN: A cohort study including all patients who started DGV in two HIV treatment centers in The Netherlands. METHODS: All cART-naïve and cART-experienced patients who had started DGV were identified from the institutional HIV databases...
November 28, 2016: AIDS
https://www.readbyqxmd.com/read/27804313/antiretroviral-treatment-for-hiv-infection-swedish-recommendations-2016
#19
Jaran Eriksen, Jan Albert, Anders Blaxhult, Christina Carlander, Leo Flamholc, Magnus Gisslén, Filip Josephson, Olof Karlström, Lars Navér, Veronica Svedhem, Aylin Yilmaz, Anders Sönnerborg
The Swedish Medical Products Agency and the Swedish Reference Group for Antiviral Therapy (RAV) have jointly published recommendations for the treatment of HIV infection on seven previous occasions (2002, 2003, 2005, 2007, 2009, 2011 and 2014). In February 2016, an expert group under the guidance of RAV once more revised the guidelines. The most important updates in the present guidelines are as follows: Tenofovir alafenamide (TAF) has recently been registered. TAF has several advantages over tenofovir disoproxilfumarate (TDF) and is recommended instead of TDF in most cases...
January 2017: Infectious Diseases
https://www.readbyqxmd.com/read/27799824/profile-of-cabotegravir-and-its-potential-in-the-treatment-and-prevention-of-hiv-1-infection-evidence-to-date
#20
REVIEW
Thomas Whitfield, Adele Torkington, Clare van Halsema
Modern antiretroviral therapy has demonstrated effectiveness in preexposure prophylaxis (PrEP) and treatment of HIV infection. There is a demand for prevention and treatment regimens that could overcome challenges of improving adherence, toxicity, and dosing convenience. Cabotegravir is an integrase strand transfer inhibitor and an analog of dolutegravir. Unlike dolutegravir, cabotegravir has a long half-life and can be formulated into a long-acting nanosuspension for parenteral administration. Initial pharmokinetic studies in humans have demonstrated adequate drug levels with intramuscular (IM) administration at 4 weekly and 8 weekly intervals, with few interactions with commonly used concomitant medications...
2016: HIV/AIDS: Research and Palliative Care
keyword
keyword
58370
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"